drugset / Trial / NCT04791553
Safety Study of Cenobamate in Subjects With Normal Hepatic Function and Subjects With Severe Hepatic Impairment
Non-randomizedParallel-groupOpen-labelOther
Summary
This study is designed investigate the effect of severe hepatic impairment on the pharmacokinetics (PK) of cenobamate.
Timeline
- Start
- 2021-06-17
- Primary completion
- 2022-11-15
- Completion
- 2023-08-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cenobamate | Small molecule | 200 mg | Oral |
Indications
No indication recorded.